Longest reported case of symptomatic COVID-19 reporting positive for over 230 days in an immunocompromised patient in the United States

Bilal Chaudhry¹, Lidiya Didenko², Maaria Chaudhry¹, Andrew Malek² and Kirill Alekseyev²

Abstract
Coronavirus 2019 (COVID-19) pneumonia was first noted in Wuhan, China. Since the start of the pandemic, there have been millions of cases diagnosed. The average time from onset of symptoms to testing negative SARS-CoV-2 via reverse transcription polymerase chain reaction is roughly 25 days. In patients who continually test positive for COVID-19, it is essential to determine precisely which risk factors contribute to the increase in viral shedding duration. We present a case about a 62-year-old man who has persistently tested positive for COVID-19 for more than 230 days. We followed his treatment course, in which he had been hospitalized multiple times since the onset of symptoms back in April 2020. We have determined that patients with immunosuppression, especially those taking corticosteroids, are at increased risk of prolonged viral shedding. It is essential to continually monitor these immunocompromised patients as they required a greater time period in order to have an appropriate immune response in which antibodies are created.

Keywords
COVID-19, reverse transcription polymerase chain reaction, viral shedding, immunocompromised, corticosteroids

Introduction
To date, there have been more than 185 million cases of COVID-19 diagnosed worldwide, and nearly 4 million deaths.² COVID-19 is commonly associated with cough, shortness of breath (SOB), fever, loss of sense of smell, and fatigue. Pre-existing conditions such as coronary artery disease, hypertension, and diabetes mellitus, and those who are immunocompromised are susceptible to complications from COVID-19.¹ The average time from onset of symptoms until patients have a negative SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) is 25 days.² There are several documented cases exist in which a prolonged duration of viral shedding has occurred in individuals with SARS-CoV-2 after being classified as asymptomatic. To date, there have been two reported cases with prolonged SARS-CoV-2 viral shedding duration greater than 100 days.³ We now present a case where a patient tested positive for 32 weeks/230 days.

Case report
We present a case about a 62-year-old man who had persistently tested positive via RT-PCR for more than 230 days. He first tested positive on 23 April 2020. He has multiple comorbidities, including systolic heart failure with a left ventricular ejection fraction of 15%, mild intermittent asthma, and hyperlipidemia. He had a history of non-Hodgkin’s lymphoma diagnosed in 2001 that was treated with Rituimab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. He has since been in remission. He also had a history of anti-neutrophil cytoplasmic antibody
COVID-19, and no further testing was ordered. He denied any associated cough, chest pain, palpitations, or nausea over the past couple of days. His maximum temperature was 38.3°C/101°F. He stated that he had an increasing cough and breathlessness without orthopnea and paroxysmal nocturnal dyspnea. Upon arrival in the ED, he was given an abuterol treatment with some improvement to his hypoxia. The patient had denied any phlegm production or expectoration. A SARS-CoV-2 RT-PCR test was ordered and returned positive. He was started on ceftriaxone and azithromycin, hydroxychloroquine, and steroids. After a short hospital stay, the patient’s oxygen level normalized on room air, and he was discharged and told to social distance.

On 21 May 2020, he visited with his primary care physician. A chest X-ray was obtained and showed improving pneumonia. He did not have any chest pain, SOB, or cough. On 22 May, he was started on cefuroxime, but the treatment failed to clear his infection. Further analysis of his complete blood count (CBC) showed that his white count showed a leukocytosis of 11.8. His white count on CBC was rechecked on 28 May and showed an increase to 14.4.

On 2 June 2020, he returned to the ED, presenting with hypotension and tachypnea. His procalcitonin was 0.09, and he was noted to be in acute renal failure with a creatinine of 1.46, while the basic metabolic panel (BMP) showed a sodium of 131. His baseline creatinine was indicated in his chart as 1.1. The results of his CBC with differential are noted in Table 1.

A chest X-ray revealed the progression of left lung opacity. A SARS-CoV-2 RT-PCR was requested and returned positive. He was given intravenous (IV) fluids and broad-spectrum antibiotics consisting of cefepime, azithromycin, and vancomycin. Rheumatology, hematology, and oncology were consulted; he received intravenous immune globulin (IVIG) as well as Rituximab. Upon discharge home, he was placed on prednisone 60 mg daily with a plan to taper slowly. He had been receiving dapsone; however, this was changed to Atovaquone.

A repeat chest computed tomography (CT) at the end of August revealed bilateral ground-glass opacities. On 1 September 2020, he presented to the ED with SOB and fevers for the past 2–3 days. The patient at baseline had been on 2L of oxygen via nasal cannula. However, starting the morning of 15 November, he had some SOB and increased his oxygen to 3L, which did not help. He also reported subjective fevers over the past couple of days, along with decreased appetite. There was epigastric abdominal pain that was constant and had been going on for the past couple of days. He denied cough, chest pain, nausea, vomiting, and diarrhea. A CT of the abdomen and pelvis was performed and revealed acute cholecystitis. CTA (computed tomography angiography) of the lung revealed multifactorial pneumonia. The surgery team was consulted, and they recommended antibiotics. He was treated with IV antibiotics and IV steroids for possible COVID-related fibrosis. Gradual improvement was noted.

On 23 November, a COVID-19 RT-PCR was requested and returned positive. On reviewing labs and physical, he was noted to have persistent idiopathic thrombocytopenic purpura (ITP), for which he was given IVIG. On 3 December, an acute change in respiratory status prompted the rapid response team to initiate respiratory distress protocols. He required an increase in high-flow nasal cannula (HFNC) from 60% to 80% FiO2 due to the saturation to mid-80s. Another SARS-CoV-2 RT-PCR was requested and returned positive.
Table 1. CBC with differential from 14 March 2020 until 20 July 2020.

|    | Normal values | 14 March 2020 | 1 June 2020 | 2 June 2020 | 0 June 2020 | 8 June 2020 | 9 June 2020 | 17 July 2020 | 20 July 2020 |
|----|---------------|---------------|-------------|-------------|-------------|-------------|-------------|--------------|--------------|
| WBC | 3.5–10.5×10⁹ L | 8.3×10⁹ L     | 5.6×10⁹ L   | 5.0×10⁹ L   | 11.3×10⁹ L (H) | 13.5×10⁹ L (H) | 13.3×10⁹ L (H) | 9.5×10⁹ L   | 13.7×10⁹ L (H) |
| HGB | 13.8–17.2 g/dL | 12.4 (L)      | 11.7 (L)    | 11.4 (L)    | 10.0 (L)    | 11.5 (L)    | 11.8 (L)    | 12.7 (L)     | 12.9 (L)     |
| HCT | 40.7%–50.3%    | 36.1 (L)      | 35.1 (L)    | 36.0 (L)    | 30.5 (L)    | 34.6 (L)    | 35.2 (L)    | 39.7 (L)     | 38.2 (L)     |
| RBC | 4.3–5.9×10¹²/L | 4.49          | 4.23 (L)    | 4.35 (L)    | 3.73 (L)    | 4.25 (L)    | 4.33 (L)    | 4.63         | 4.58         |
| MCV | 80–100 μm³     | 80.4          | 83.0        | 82.8        | 81.8        | 81.4        | 81.3        | 85.7         | 83.4         |
| MCH | 26.4–35.6 pg/cell | 27.6        | 27.7        | 26.2 (L)    | 26.8        | 27.1        | 27.3        | 27.4         | 28.2         |
| MCHC| 31–36g/dL      | 34.3          | 33.3        | 31.7        | 32.8        | 33.2        | 33.5        | 32.0         | 33.8         |
| RDW | 11.8%–15.6%    | 13.2          | 17.0 (H)    | 16.7 (H)    | 16.3 (H)    | 16.5 (H)    | 17.3 (H)    | 17.8 (H)     | 16.7 (H)     |
| MPV | 7.5–12.0 fl    | 9.8           | 8.7         | 9.1         | 9.5         | 9.7         | 9.3         | 10.0         | 9.8          |
| Platelet | 150–400×10⁹/L | 197          | 321         | 397         | 358         | 357         | 326         | 267          | 248          |
| Ab. IG | <0.1/nL      | 0.0          | 0.9 (H)     | 0.1 (H)     | 0.1 (H)     | 0.1 (H)    |             |             |             |
| Ab. Lymph | 0.9–4.4/nL  | 1.1          | 1.1         | 0.7 (L)     | 1.1         | 1.1         |             |             |             |
| Ab. Mono | 0.1–1.1/nL   | 0.7          | 0.7         | 0.1         | 0.7         | 0.7         |             |             |             |
| Ab. Eos | 0.0–0.3/nL   | 0.4 (H)      | 0.2         | <0.1        | <0.1        | <0.1        |             |             |             |
| Ab. Baso | 0.0–0.1/nL   | 0.0          | 0.0         | 0.0         | 0.0         | 0.0         |             |             |             |
| Automated neutrophil | 50%–60% | 72.6 (H) | 61.9 (H) | 82.9 (H) | 86.4 (H) |             |             |             |             |
| Fibrinogen | 15–300 μg/L | 654 (H)     |             |             |             |             |             | 298          |             |
| D-Dimer | <250ng/mL    | 401 (H)      |             |             |             |             |             |             | <150         |

WBC: white blood cell; HGB: hemoglobin; RBC: red blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red cell distribution width; MPV: mean platelet value; Ab. IG: absolute immature granulocyte; Ab. Lymph: absolute lymphocyte; Ab. Mono: absolute monocyte; Ab. Eos: absolute eosinophil; Ab. Baso: absolute basophil.
Our patient first tested positive for COVID-19 on 23 April 2020 and has since tested positive for 32 weeks/230 days. There have been only two other reported cases with prolonged SARS-CoV-2 viral shedding duration greater than 100 days.3,4 There have been several documented cases in which a prolonged duration of viral shedding has occurred in individuals with SARS-CoV-2 after being classified as asymptomatic. The extended period of viral shedding in these individuals has been concomitant with fever, time from symptomology onset to hospitalization, age, and corticosteroid use.1 All of these factors were observed in our patient, as he continually tested positive. Prolonged viral shedding duration has also been linked to lower lymphocyte levels and elevated ferritin, C-reactive protein, and neutrophil count.5 Patients who are immunocompromised are likely to have long-term shedding due to atypical symptom presentation. There are two explanations for why immunocompromised individuals continuously test positive via PCR: either they are shedding residual RNA or shedding the infectious replication-competent virus.6 It is thought that immunosuppression with persistent viral shedding may be a protective factor because of the reduced immune response. The use of Rituximab, a monoclonal antibody, dampens the seroconversion immune response.1

Patients who are immunocompromised are likely to have long-term shedding due to atypical symptom presentation. There are two explanations for why immunocompromised individuals continuously test positive via PCR: either they are shedding residual RNA or shedding the infectious replication-competent virus.6 It is thought that immunosuppression with persistent viral shedding may be a protective factor because of the reduced immune response. The use of Rituximab, a monoclonal antibody, dampens the seroconversion immune response.1

A recent study conducted by Prescott et al.8 found that immunocompromised animal subjects exhibited even more prolonged viral shedding than their immunocompetent counterparts. There was earlier detection of viral RNA and elevated viral RNA levels in the respiratory tract tissues in these animal subjects. Furthermore, the immunocompromised animal subjects exhibited significantly milder pathology because of the dampened immunological response. It can be presumed that viral replications will be much higher in the absence of a proficient immune reaction, while an exaggerated inflammatory response will likely lead to pathology.7

Persistent viral shedding is more common in older patients, especially those with a higher viral load.1 While many COVID-19 patients attain a clinical recovery, a small percentage of patients may have persistent viral shedding that should be monitored.8 It is imperative to monitor patients who are immunocompromised, those taking corticosteroids, and those with signs of elevated inflammatory markers.

Furthermore, although our patient had one COVID-19 antibody test that was negative, he displayed symptoms and clinical evidence of having contracted the virus. His diagnosis was confirmed through multiple positive RT-PCRs, as depicted in Table 2. The Food and Drug Administration (FDA) urges healthcare providers not to use antibody tests to diagnose active COVID-19 infections. A positive antibody test only indicates that a patient has been infected with coronavirus in the past. It often takes days and even several weeks for the immune system to create enough antibodies to be detected in a test.9,10 Therefore, immunocompromised individuals, such as our patient, may take months to produce an appropriate number of antibodies to yield a positive antibody test.

In addition, several studies confirm that molecular diagnostic tests, such as RT-PCR, should be used as the gold standard for diagnosing patients with coronavirus. They have found that antibody tests yield a sensitivity of 77.3% with a false-negative rate of 22.7%.11 Thus, it is fair to consider that the negative antibody test on 3 June represented a false negative.

### Conclusion

Our patient tested positive for SARS-CoV-2 for more than 230 days. During this time, he was hospitalized multiple times and was treated appropriately. With the continuous rise in COVID-19 cases worldwide, healthcare providers need to note the various presentations and length of disease seen in patients who have contracted the virus. The average immunocompetent patient tests negative 25 days after the manifestation of coronavirus symptoms and immunocompromised patients may continue to have positive RT-PCR for weeks, and in rare cases, months after the symptom onset. As seen in our patient, it is crucial to monitor these immunocompromised patients continually.

### Authors’ Note

Andrew Malek is now affiliated to Institute For Family Health, Kingston, NY.

---

**Table 2.** Patient’s CRP level, COVID test, and COVID test result for each admission.

| Date               | Test  | COVID +/− | CRP (mg/L) |
|--------------------|-------|-----------|------------|
| 23 April 2020      | RT-PCR| +         | 182.5      |
| 3 June 2020        | IgG   | <1.01     | 151        |
| 1 September 2020   | RT-PCR| +         | 37.6       |
| 3 September 2020   | RT-PCR| +         | 135.9      |
| 1 October 2020     | RT-PCR| +         | 227.8      |
| 10 October 2020    | RT-PCR| +         | 107.1      |
| 23 November 2020   | RT-PCR| +         | 78.6       |
| 3 December 2020    | RT-PCR| +         | 40.3       |

RT-PCR: reverse transcription polymerase chain reaction; IgG: immunoglobulin G.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iDs
Lidiya Didenko https://orcid.org/0000-0003-3066-8135
Maaria Chaudhry https://orcid.org/0000-0002-0199-1294
Andrew Malek https://orcid.org/0000-0001-9583-198X

References
1. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 2020; 183(7): 1901–1912.e9.
2. COVID—19 map—Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html (accessed 22 July 2021).
3. Li T-Z, Cao Z-H, Chen Y, et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol 2021; 93(1): 506–512.
4. Gombar S, Chang M, Hogan CA, et al. Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19. J Clin Virol 2020; 129: 104477.
5. Cho SM and Ha GY. A case of COVID-19 in a 45-day-old infant with persistent fecal virus shedding for more than 12 weeks. Yonsei Med J 2020; 61(10): 901–903.
6. Gao C, Zhu L, Jin CC, et al. Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. Clin Immunol 2020; 221: 108611.
7. Daniel P, Raad M, Waked R, et al. COVID-19 in a patient treated for granulomatosis with polyangiitis: persistent viral shedding with no cytokine storm. Eur J Case Rep Intern Med 2020; 7(10): 001922.
8. Prescott J, Falzarano D, de Wit E, et al. Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques. Front Immunol 2018; 9: 205.
9. Hartman WR, Hess AS and Connor JP. Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors. Transfusion 2020; 60(10): 2189–2191.
10. Office of the Commissioner. Coronavirus Disease 2019 Testing Basics. https://www.fda.gov/consumers/consumer-updates/coronavirus-disease-2019-testing-basics (2021, accessed 23 July 2021).
11. Xiang F, Wang X, He X, et al. Antibody detection and dynamic characteristics in patients with Coronavirus disease 2019. Clin Infect Dis 2020; 71(8): 1930–1934.